Home
>
US Stocks
>
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
CBAY

Cymabay Therapeutics Inc

$3.913.71%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
4.01
Today Low/High
3.88 / 4.01
52 Week Low/High
$3.5 / $9.06
Market Cap
$244.25M

Company Details

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.
Organisation
Cymabay Therapeutics Inc
Headquaters
Newark, California, US
Employees
44
Industry
Health Technology
CEO
Sujal Shah

Discover more

Frequently Asked Questions

What is Cymabay Therapeutics Inc share price today

Can Indians buy Cymabay Therapeutics Inc shares?

How can I buy Cymabay Therapeutics Inc shares from India?

Can Fractional shares of Cymabay Therapeutics Inc be purchased?

What are the documents required to start investing in Cymabay Therapeutics Inc stocks?

We are a SEBI registered investement advisor